Hypermobility syndrome represents a complex clinical picture that is often neglected by health professionals, said Rodney Grahame, MD, Consultant Rheumatologist, The Hypermobility Unit at the Hospital of St. John and St. Elizabeth, London, England, at the 9th Annual Rheumatology Nurses Society Conference.
In patients with rheumatoid arthritis (RA), fatigue is a significant predictor of high healthcare costs, reduced physical functioning, and poor quality of life. Fatigue has also been shown to persist in this patient population, even when disease remission is achieved, according to the results of a recent study.
Long-term 104-week follow-up of the phase 3 MEASURE 2 study confirmed sustained secukinumab efficacy and safety for signs and symptoms of active ankylosing spondylitis (AS), stated Helena Marzo-Ortega, PhD, Honorary Clinical Assistant Professor, University of Leeds, United Kingdom, in a 2016 European League Against Rheumatism Annual Congress presentation.
- Adalimumab Biosimilar FDA-Approved to Treat Multiple Indications
- First Drug for Duchenne Muscular Dystrophy Granted Accelerated Approval
- FDA Approves Etanercept Biosimilar for Multiple Indications
- Routine Monitoring of Drug Levels and Antidrug Antibodies Benefits Cost, Improves Treatment Decision-Making
- Switching Between Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
- Tofacitinib Treatment Demonstrates Cost Benefits in Patients with Rheumatoid Arthritis
Up to 40% of patients with rheumatic diseases will have neuropathies attributable to competing disorders. These competing comorbidities may encapsulate many different syndromes. Using the VITAMINS mnemonic may help to distinguish between neuropathies caused by rheumatic diseases versus those caused by competing morbidities, said Julius Birnbaum, MD, Assistant Professor of Medicine and Neurology, The Johns Hopkins Hospital, Baltimore, MD, at the 9th Annual Rheumatology Nurses Society Conference.
Four-Year Trial Outcomes Show Sustained Certolizumab Pegol Efficacy in Patients with Axial Spondyloarthritis
Treatment efficacy of certolizumab pegol was maintained for more than 4 years in patients with axial spondyloarthritis (axSpA) enrolled in the RAPID-axSpA clinical trial, according to a presentation at the 2016 European League Against Rheumatism Annual Congress. Certolizumab pegol is a monoclonal antibody to tumor necrosis factor (TNF)-α, said lead investigator Désirée van der Heijde, MD, Professor of Rheumatology, Leiden University Medical Center, The Netherlands. AxSpA is a chronic inflammatory disease characterized primarily by inflammation of the sacroiliac joints and spine, which leads to chronic back pain.
Exercise significantly reduced symptoms of depression in patients with fibromyalgia, osteoarthritis, rheumatoid arthritis, and systemic lupus erythematosus, according to the results of a recent study by George A. Kelley, PhD, Professor, and Kristi S. Kelley, MEd, Research Instructor, Department of Biostatistics, School of Public Health, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown.
Elderly patients (aged ≥60 years) with rheumatoid arthritis (RA) may be less likely to receive treatment with tumor necrosis factor (TNF) inhibitors than younger patients with RA because of concerns about comorbidities and adverse events. However, a new study by Soo-Kyung Cho, MD, PhD, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, and colleagues shows that elderly patients who are prescribed these drugs have retention rates comparable to those of younger patients.
Women with rheumatoid arthritis (RA) had a 40% greater risk for mortality than women without RA during 36 years of follow-up in a longitudinal cohort study.
Page 1 of 2
Results 1 - 10 of 16
Results 1 - 10 of 16